Skandinaviska Enskilda Banken AB publ Decreases Holdings in Elevance Health, Inc. $ELV

Skandinaviska Enskilda Banken AB publ lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 24.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 47,399 shares of the company’s stock after selling 15,128 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Elevance Health were worth $15,316,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. denkapparat Operations GmbH increased its stake in Elevance Health by 49.1% in the third quarter. denkapparat Operations GmbH now owns 2,332 shares of the company’s stock valued at $754,000 after purchasing an additional 768 shares during the last quarter. M&G PLC grew its position in shares of Elevance Health by 9.1% in the 3rd quarter. M&G PLC now owns 1,015,113 shares of the company’s stock valued at $327,881,000 after buying an additional 84,820 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after buying an additional 141,747 shares during the last quarter. Tobam raised its stake in Elevance Health by 1,272.0% during the 3rd quarter. Tobam now owns 7,244 shares of the company’s stock worth $2,341,000 after acquiring an additional 6,716 shares in the last quarter. Finally, Pallas Capital Advisors LLC lifted its position in Elevance Health by 390.5% in the third quarter. Pallas Capital Advisors LLC now owns 2,943 shares of the company’s stock valued at $951,000 after acquiring an additional 2,343 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of ELV opened at $344.40 on Wednesday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The stock’s 50 day moving average is $352.83 and its two-hundred day moving average is $333.24. The firm has a market capitalization of $76.01 billion, a PE ratio of 13.71, a P/E/G ratio of 1.93 and a beta of 0.50. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same period last year, the firm earned $3.84 EPS. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.39%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Mizuho set a $413.00 target price on Elevance Health in a research report on Friday, January 9th. Leerink Partners lifted their price target on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Wells Fargo & Company decreased their price objective on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $332.00 price target on shares of Elevance Health in a research note on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.